Doses of Wegovy - Search News

Wegovy, Novo Nordisk

Novo’s Wegovy Trails Lilly’s Rival in High-Dose Study

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early dominance in the surging market for new weight-loss treatments.

MarketWatch on MSN · 12h

Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

STAT · 11h

High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.

Seeking Alpha on MSN · 13h

Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial

Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.

Wegovy included

The Associated Press on MSN · 9h

Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.

STAT · 8h

Medicare announces plan to negotiate prices of diabetes, weight loss drugs

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

Orange County Register · 9h

Ozempic and Wegovy among drugs on Medicare list getting price cuts

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

11h

Wegovy at Higher Dose Achieves Greater Weight Loss in Trial

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

12h

Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

12hon MSN

Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

BioSpace9h

Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

FiercePharma12h

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

BioPharma Dive5h

Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Wegovy, Novo Nordisk

Wegovy included

Related topics